Alzamend Neuro, Inc.
ALZN
$2.96
-$0.03-1.00%
NASDAQ
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.69% | -43.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.78% | -23.61% | |||
| Operating Income | -9.78% | 23.61% | |||
| Income Before Tax | -9.62% | 23.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.62% | 23.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.62% | 23.66% | |||
| EBIT | -9.78% | 23.61% | |||
| EBITDA | -9.92% | 23.84% | |||
| EPS Basic | -43.44% | 52.99% | |||
| Normalized Basic EPS | 5.51% | 51.14% | |||
| EPS Diluted | -43.44% | 52.99% | |||
| Normalized Diluted EPS | 5.51% | 51.14% | |||
| Average Basic Shares Outstanding | 16.02% | 56.24% | |||
| Average Diluted Shares Outstanding | 16.02% | 56.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||